Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Uveal Melanoma 1Pancreatic Neoplasms 1Lung Neoplasms 1Glioblastoma 1Carcinoma, Endometrioid 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 177Radiotherapy 139Cisplatin 110Pemetrexed 102Docetaxel 93Paclitaxel 92Gemcitabine 78Erlotinib Hydrochloride 73Magnetic Resonance Spectroscopy 72Radiosurgery 67Bevacizumab 65pembrolizumab 64Etoposide 60Blood Specimen Collection 60durvalumab 53Specimen Handling 48Nivolumab 48Surveys and Questionnaires 47Drug Therapy 41Standard of Care 35Radiation 33osimertinib 32atezolizumab 32Surgical Procedures, Operative 30Topotecan 29Irinotecan 29Gefitinib 29Educational Status 29Early Intervention, Educational 29Biopsy 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lung Neoplasms × RO5126766 × Clear all
NCT06495125 2026-04-06

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Emory University

Phase 2 Recruiting
50 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡